A total of 173 patients with metastatic (a cancer that has spread to other organs) TNBC were involved in the study. 115 patients were assigned to receive cisplatin and cetuximab together, while 58 patients received cisplatin alone.
20% of the patients treated with cisplatin plus cetuximab showed some response to treatment, compared to only 10% of patients treated with cisplatin alone. Patients receiving cetuximab experienced a longer period of time before progression of the cancer occurred. Overall survival was also prolonged with cetuximab treatment. However, 61% of patients in the cisplatin plus cetuximab group experienced serious adverse events, compared to 42% of patients receiving cisplatin alone.
In summary, this study demonstrated that treatment with cisplatin plus cetuximab shows an increased benefit and improved overall survival compared to treatment with cisplatin alone.
This study is an early phase trial. Further research and larger control trials are necessary to verify these findings.
Consult with your physician on the use of cetuximab in the treatment of metastatic triple negative breast cancer.
Published By :
Journal of clinical oncology
Date :
Jun 03, 2013
